Sanofi sues Merck over Lantus patents
Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus (insulin glargine injection) and Lantus SoloSTAR.
The complaint was filed in the US District Court for the District of Delaware on September 16.
Lantus and Lantus SoloSTAR are treatments for patients suffering with diabetes.
The case arose after Merck submitted a New Drug Application to the Food and Drug Administration (FDA) seeking the FDA’s approval to commercially manufacture and sell a generic version of the drug.
Sanofi has asked the district court to give a permanent injunction preventing Merck from bringing the generic version of the drug to the market before the expiration of the patents involved.
The French-based company is also asking the court to order an award of expenses and attorneys’ fees.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk